Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IV Multi-Centric Post-Marketing Study Evaluating the Safety, Immunogenicity and EFFICACY of the Marketed Formulation of Hetero - Rituximab

Trial Profile

A Phase IV Multi-Centric Post-Marketing Study Evaluating the Safety, Immunogenicity and EFFICACY of the Marketed Formulation of Hetero - Rituximab

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia; Microscopic polyangiitis; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis
  • Focus Adverse reactions
  • Sponsors Hetero Drugs
  • Most Recent Events

    • 25 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top